COMMUNIQUÉS West-GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/11/2025
WESTLAKE VILLAGE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]
Exicure, Inc. Reports Third Quarter 2025 Financial Results
07/11/2025
REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the fiscal quarter ended September 30, 2025. Third Quarter 2025 Financial [...]
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/11/2025
NAARDEN, The Netherlands and MIAMI, Nov. 07, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]
BillionToOne Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
07/11/2025
MENLO PARK, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the closing of [...]
Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week
07/11/2025
WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet [...]
InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria
07/11/2025
Company expects to host a webcast to discuss the topline data on Monday, November 10 at 8:00 AM EST / 2:00 PM CET Company also expects to publish third quarter 2025 financial results on the same day pre-market JENA, [...]
Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update
07/11/2025
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt [...]
Arcadia Biosciences (RKDA) Announces Third Quarter 2025 Financial Results and Business Highlights
07/11/2025
-- Zola ® year-to-date revenues increase 26% year over year -- -- Arcadia gross profit margins exceed 30% for 11 th straight quarter -- -- Arcadia cash balance declines by only $257K to $1.1M -- DALLAS, Nov. 07, 2025 ( [...]
Nanox to Report Third Quarter 2025 Financial Results on November 20, 2025
07/11/2025
PETACH TIKVA, Israel, Nov. 07, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial [...]
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/11/2025
BRISBANE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on November 4, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted [...]
Spyre Therapeutics Announces Grants of Inducement Awards
07/11/2025
WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to [...]
Cellectis publie ses résultats financiers du troisième trimestre 2025 et une mise à jour de ses activités
07/11/2025
Les données présentées confirment le potentiel de lasmé-cel (UCART22) et d’éti-cel (UCART20x22) pour améliorer les résultats cliniques dans la LAL-B et le LNH en rechute ou réfractaire : Lasmé-cel dans la LAL-B en [...]
Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update
07/11/2025
Presented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL: Lasme-cel in r/r B-ALL (BALLI-01) ORR of 68% with lasme-cel Process 2 (n=22), 83% at [...]
Cannabix Technologies announces Non-Brokered LIFE Private Placement
07/11/2025
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (the “Company or [...]
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
07/11/2025
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/11/2025
CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with [...]
Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)
07/11/2025
Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade in advanced melanoma following definitive anti-PD-1 failure WOBURN, Mass., Nov. 07, 2025 (GLOBE [...]
Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01
07/11/2025
New biomarker and immune data presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting Following the recent presentation of unprecedented two-year clinical efficacy data from the phase 2 trial, [...]
Chemed Corporation Declares Quarterly Dividend of 60 Cents
07/11/2025
CINCINNATI, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 60-cents per share on the Company’s capital stock, [...]

Pages